Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine

Frederic Lapostolle; Arnoud W. van't Hof; Christian W. Hamm; Olivier Stibbe; Patrick Ecollan; Jean-Philippe Collet; Johanne Silvain; Jens Flensted Lassen; Wim M. J. M. Heutz; Leonardo Bolognese; Warren J. Cantor; Angel Cequier; Mohamed Chettibi; Shaun G. Goodman; Christopher Hammett; Kurt Huber; Magnus Janzon; Bela Merkely; Robert F. Storey; Jur ten Berg; Uwe Zeymer; Muriel Licour; Anne Tsatsaris; Gilles Montalescot; Rachid Bougherbal; Mohamed Tahar Bouafia; Mohamed Chettibi; Djamaleddine Nibouche; Abdelkader Moklati; Ahmed Benalia; Messaad Krim; Christopher Hammett; Paul Garraby; Rohan Jayasinghe; Stephen Rashford; Kurt Huber; Thomas Neunteufl; Helmut Brussee; Hannes Alber; Franz Weidinger; Michael Baubin; Dieter Sebald; Warren Cantor; Ram Vijayaraghavan; Iqbal Bata; Andrea Lavoie; Jens Flensted Lassen; Jan Ravkilde; Lisette Okkels Jensen; Alf Mol Christensen; ATLANTIC Investigators

doi:10.1007/s40256-018-0305-0

Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine

Frederic Lapostolle, Arnoud W. van't Hof, Christian W. Hamm, Olivier Stibbe, Patrick Ecollan, Jean-Philippe Collet, Johanne Silvain, Jens Flensted Lassen, Wim M. J. M. Heutz, Leonardo Bolognese, Warren J. Cantor, Angel Cequier, Mohamed Chettibi, Shaun G. Goodman, Christopher Hammett, Kurt Huber, Magnus Janzon, Bela Merkely, Robert F. Storey, Jur ten BergUwe Zeymer, Muriel Licour, Anne Tsatsaris, Gilles Montalescot^*, Rachid Bougherbal, Mohamed Tahar Bouafia, Mohamed Chettibi, Djamaleddine Nibouche, Abdelkader Moklati, Ahmed Benalia, Messaad Krim, Christopher Hammett, Paul Garraby, Rohan Jayasinghe, Stephen Rashford, Kurt Huber, Thomas Neunteufl, Helmut Brussee, Hannes Alber, Franz Weidinger, Michael Baubin, Dieter Sebald, Warren Cantor, Ram Vijayaraghavan, Iqbal Bata, Andrea Lavoie, Jens Flensted Lassen, Jan Ravkilde, Lisette Okkels Jensen, Alf Mol Christensen, ATLANTIC Investigators

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

BackgroundMorphine adversely impacts the action of oral adenosine diphosphate (ADP)-receptor blockers in ST-segment elevation myocardial infarction (STEMI) patients, and is possibly associated with differing patient characteristics. This retrospective analysis investigated whether interaction between morphine use and pre-percutaneous coronary intervention (pre-PCI) ST-segment elevation resolution in STEMI patients in the ATLANTIC study was associated with differences in patient characteristics and management.MethodsATLANTIC was an international, multicenter, randomized study of treatment in the acute ambulance/hospital setting where STEMI patients received ticagrelor 180mgmorphine. Patient characteristics, cardiovascular history, risk factors, management, and outcomes were recorded.ResultsOpioids (97.6% morphine) were used in 921 out of 1862 patients (49.5%). There were no significant differences in age, sex or cardiovascular history, but more morphine-treated patients had anterior myocardial infarction and left-main disease. Time from chest pain to electrocardiogram and ticagrelor loading was shorter with morphine (both p=0.01) but not total ischemic time. Morphine-treated patients more frequently received glycoprotein IIb/IIIa inhibitors (p=0.002), thromboaspiration and stent implantation (both p

Original language	English
Pages (from-to)	173-183
Number of pages	11
Journal	American Journal of Cardiovascular Drugs
Volume	19
Issue number	2
DOIs	https://doi.org/10.1007/s40256-018-0305-0
Publication status	Published - Apr 2019

Keywords

DOUBLE-BLIND
ASSOCIATION
REPERFUSION
PRASUGREL
OUTCOMES
INSIGHTS
TRIAL

Access to Document

10.1007/s40256-018-0305-0

Cite this

Lapostolle, F., van't Hof, A. W., Hamm, C. W., Stibbe, O., Ecollan, P., Collet, J.-P., Silvain, J., Lassen, J. F., Heutz, W. M. J. M., Bolognese, L., Cantor, W. J., Cequier, A., Chettibi, M., Goodman, S. G., Hammett, C., Huber, K., Janzon, M., Merkely, B., Storey, R. F., ... ATLANTIC Investigators (2019). Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine. American Journal of Cardiovascular Drugs, 19(2), 173-183. https://doi.org/10.1007/s40256-018-0305-0

@article{62a8b3df6e3342f0b7eed7381bd31b90,

title = "Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine",

abstract = "BackgroundMorphine adversely impacts the action of oral adenosine diphosphate (ADP)-receptor blockers in ST-segment elevation myocardial infarction (STEMI) patients, and is possibly associated with differing patient characteristics. This retrospective analysis investigated whether interaction between morphine use and pre-percutaneous coronary intervention (pre-PCI) ST-segment elevation resolution in STEMI patients in the ATLANTIC study was associated with differences in patient characteristics and management.MethodsATLANTIC was an international, multicenter, randomized study of treatment in the acute ambulance/hospital setting where STEMI patients received ticagrelor 180mgmorphine. Patient characteristics, cardiovascular history, risk factors, management, and outcomes were recorded.ResultsOpioids (97.6% morphine) were used in 921 out of 1862 patients (49.5%). There were no significant differences in age, sex or cardiovascular history, but more morphine-treated patients had anterior myocardial infarction and left-main disease. Time from chest pain to electrocardiogram and ticagrelor loading was shorter with morphine (both p=0.01) but not total ischemic time. Morphine-treated patients more frequently received glycoprotein IIb/IIIa inhibitors (p=0.002), thromboaspiration and stent implantation (both p",

keywords = "DOUBLE-BLIND, ASSOCIATION, REPERFUSION, PRASUGREL, OUTCOMES, INSIGHTS, TRIAL",

author = "Frederic Lapostolle and {van't Hof}, {Arnoud W.} and Hamm, {Christian W.} and Olivier Stibbe and Patrick Ecollan and Jean-Philippe Collet and Johanne Silvain and Lassen, {Jens Flensted} and Heutz, {Wim M. J. M.} and Leonardo Bolognese and Cantor, {Warren J.} and Angel Cequier and Mohamed Chettibi and Goodman, {Shaun G.} and Christopher Hammett and Kurt Huber and Magnus Janzon and Bela Merkely and Storey, {Robert F.} and {ten Berg}, Jur and Uwe Zeymer and Muriel Licour and Anne Tsatsaris and Gilles Montalescot and Rachid Bougherbal and Bouafia, {Mohamed Tahar} and Mohamed Chettibi and Djamaleddine Nibouche and Abdelkader Moklati and Ahmed Benalia and Messaad Krim and Christopher Hammett and Paul Garraby and Rohan Jayasinghe and Stephen Rashford and Kurt Huber and Thomas Neunteufl and Helmut Brussee and Hannes Alber and Franz Weidinger and Michael Baubin and Dieter Sebald and Warren Cantor and Ram Vijayaraghavan and Iqbal Bata and Andrea Lavoie and Lassen, {Jens Flensted} and Jan Ravkilde and Jensen, {Lisette Okkels} and Christensen, {Alf Mol} and {ATLANTIC Investigators}",

note = "Funding Information: had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. The authors would like to thank Richard Cairns, from Worldwide Clinical Trials UK, for statistical analysis. Editorial support was provided by Liz Anfield, Prime, Knutsford, Cheshire, funded by AstraZeneca. All persons named in the acknowledgements section have provided the corresponding author with written permission to be named in the article. ATLANTIC study investigators Algeria: Rachid Bougherbal (Algiers), Mohamed Tahar Boua-fia (Algiers), Mohamed Chettibi (Algiers), Djamaleddine Nibouche (Medea), Abdelkader Moklati (Tipaza), Ahmed Benalia (Algiers), Omar Kaid (Blida), Messaad Krim (Blida). Funding Information: Funding This work was supported by AstraZeneca and led by the ACTION Group (Allies in Cardiovascular Trials Initiatives and Organized Networks), www.action-coeur.org. Funding Information: Conflict of interest All authors have completed the International Committee of Medical Journal Editors (ICMJE) Form for Disclosure of Potential Conflicts of Interest. Fr{\'e}d{\'e}ric Lapostolle has received research grants, consultancy fees and honoraria from AstraZeneca, Merck-Serono, Roche, Boehringer-Ingelheim, Bayer, The Medicines Company, Correvio, Daiichi-Sankyo, and Eli-Lilly. Arnoud W. van {\textquoteleft}t Hof has received research grants, consultancy fees and honoraria from AstraZeneca, Medtronic, Daiichi-Sankyo, and Iroko Cardio. Christian W. Hamm has received research grants, consultancy fees, and honoraria from AstraZeneca, Daiichi-Sankyo, Lilly, Sanofi-Aventis, and Boehringer-Ingelheim. Patrick Ecollan has received consultancy fees from AstraZeneca, Abbott Vascular, Eli-Lilly, Sanofi-Aventis, and Biom{\'e}rieux. Jean-Philippe Collet has received research grants from Bristol-Myers Squibb; consulting fees from Bristol-Myers Squibb, Eli Lilly, and Sanofi-Aventis; and lecture fees from Bristol-Myers Squibb and Sanofi-Aventis. Johanne Silvain has received research grants from F{\'e}d{\'e}ration Fran{\c c}aise de Cardiologie and Soci{\'e}t{\'e} Fran{\c c}aise de Cardi-ologie; consultancy fees and honoraria from Amgen, Algorythm As-traZeneca, Bayer, Gilead Science and Sanofi-Aventis; and travel support from Amgen, AstraZeneca, Bayer and Bristol-Myers Squibb. Jens Flensted Lassen has received honoraria from AstraZeneca. Leonardo Bolognese has received consultancy fees and honoraria from Astra-Zeneca, Daiichi-Sankyo, Eli-Lilly, Menarini Ind Farma, and Abbott. Warren J. Cantor has received honoraria from AstraZeneca. Mohamed Chettibi has received support from AstraZeneca (study investigator). Shaun G. Goodman has received support from AstraZeneca Canada (National [Canada] Coordinator) and consultancy fees and honoraria from AstraZeneca, Eli-Lilly, and Sanofi. Christopher J. Hammett has received research grants from AstraZeneca and consultancy fees and honoraria from AstraZeneca, Eli-Lilly, Bayer Healthcare, Boehringer-Ingelheim, Amgen, and The Medicines Company. Magnus Janzon has received support from AstraZeneca (National Coordinating Investigator) and Pfizer. Robert Storey has received research grants, consultancy fees and honoraria from AstraZeneca; research grants and consultancy fees from PlaqueTec; consultancy fees from Actelion/Idorsia, Avacta, Bayer, Bristol-Myers Squibb, Pfizer, Novartis, and The Medicines Company. Jur ten Berg has received research grants, consultancy fees and honoraria from AstraZeneca. Uwe Zeymer has received research grants from Daiichi-Sankyo, Eli-Lilly, Novartis and Sanofi and consultancy fees and honoraria from AstraZeneca, Bayer Healthcare, The Medicines Company, Daiichi-Sankyo, Eli-Lilly, Novartis, Sanofi, Boehringer-Ingelheim, and Merck-Sharp and Dohme. Gilles Montale-scot has received research grants (institution) from ADIR, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Celladon, Daiichi-Sankyo, Eli-Lilly, ICAN, F{\'e}d{\'e}ration Fran{\c c}aise de Cardiologie, Medtronic, Merck-Sharp and Dohme, Pfizer, Sanofi-Aventis, and The Medicines Company and consultancy fees from Am-gen, AstraZeneca, Bayer, Berlin Chimie AG, Boehringer-Ingelheim, Bristol-Myers Squibb, Beth Israel Deaconess Medical, Brigham Women{\textquoteright}s Hospital, Cardiovascular Research Foundation, CME Resources, Daiichi-Sankyo, Eli-Lilly, Europa, Elsevier, Fondazione Anna Maria Sechi per il Cuore, Gilead, Janssen, Lead-Up, Menarini, Merck-Sharp and Dohme, Pfizer, Sanofi-Aventis, The Medicines Company, TIMI Study Group, and WebMD. Muriel Licour and Anne Tsatsaris are employees of AstraZeneca, while Angel Cequier, B{\'e}la Merkely, Kurt Hu-ber, Olivier Stibbe, and Wim M.J.M. Heutz have nothing to disclose. Publisher Copyright: {\textcopyright} 2018, Springer Nature Switzerland AG.",

year = "2019",

month = apr,

doi = "10.1007/s40256-018-0305-0",

language = "English",

volume = "19",

pages = "173--183",

journal = "American Journal of Cardiovascular Drugs",

issn = "1175-3277",

publisher = "Adis International Ltd",

number = "2",

}

Lapostolle, F, van't Hof, AW, Hamm, CW, Stibbe, O, Ecollan, P, Collet, J-P, Silvain, J, Lassen, JF, Heutz, WMJM, Bolognese, L, Cantor, WJ, Cequier, A, Chettibi, M, Goodman, SG, Hammett, C, Huber, K, Janzon, M, Merkely, B, Storey, RF, ten Berg, J, Zeymer, U, Licour, M, Tsatsaris, A, Montalescot, G, Bougherbal, R, Bouafia, MT, Chettibi, M, Nibouche, D, Moklati, A, Benalia, A, Krim, M, Hammett, C, Garraby, P, Jayasinghe, R, Rashford, S, Huber, K, Neunteufl, T, Brussee, H, Alber, H, Weidinger, F, Baubin, M, Sebald, D, Cantor, W, Vijayaraghavan, R, Bata, I, Lavoie, A, Lassen, JF, Ravkilde, J, Jensen, LO, Christensen, AM & ATLANTIC Investigators 2019, 'Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine', American Journal of Cardiovascular Drugs, vol. 19, no. 2, pp. 173-183. https://doi.org/10.1007/s40256-018-0305-0

Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine. / Lapostolle, Frederic; van't Hof, Arnoud W.; Hamm, Christian W. et al.
In: American Journal of Cardiovascular Drugs, Vol. 19, No. 2, 04.2019, p. 173-183.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction

T2 - ATLANTIC-Morphine

AU - Lapostolle, Frederic

AU - van't Hof, Arnoud W.

AU - Hamm, Christian W.

AU - Stibbe, Olivier

AU - Ecollan, Patrick

AU - Collet, Jean-Philippe

AU - Silvain, Johanne

AU - Lassen, Jens Flensted

AU - Heutz, Wim M. J. M.

AU - Bolognese, Leonardo

AU - Cantor, Warren J.

AU - Cequier, Angel

AU - Chettibi, Mohamed

AU - Goodman, Shaun G.

AU - Hammett, Christopher

AU - Huber, Kurt

AU - Janzon, Magnus

AU - Merkely, Bela

AU - Storey, Robert F.

AU - ten Berg, Jur

AU - Zeymer, Uwe

AU - Licour, Muriel

AU - Tsatsaris, Anne

AU - Montalescot, Gilles

AU - Bougherbal, Rachid

AU - Bouafia, Mohamed Tahar

AU - Chettibi, Mohamed

AU - Nibouche, Djamaleddine

AU - Moklati, Abdelkader

AU - Benalia, Ahmed

AU - Krim, Messaad

AU - Hammett, Christopher

AU - Garraby, Paul

AU - Jayasinghe, Rohan

AU - Rashford, Stephen

AU - Huber, Kurt

AU - Neunteufl, Thomas

AU - Brussee, Helmut

AU - Alber, Hannes

AU - Weidinger, Franz

AU - Baubin, Michael

AU - Sebald, Dieter

AU - Cantor, Warren

AU - Vijayaraghavan, Ram

AU - Bata, Iqbal

AU - Lavoie, Andrea

AU - Lassen, Jens Flensted

AU - Ravkilde, Jan

AU - Jensen, Lisette Okkels

AU - Christensen, Alf Mol

AU - ATLANTIC Investigators

N1 - Funding Information: had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. The authors would like to thank Richard Cairns, from Worldwide Clinical Trials UK, for statistical analysis. Editorial support was provided by Liz Anfield, Prime, Knutsford, Cheshire, funded by AstraZeneca. All persons named in the acknowledgements section have provided the corresponding author with written permission to be named in the article. ATLANTIC study investigators Algeria: Rachid Bougherbal (Algiers), Mohamed Tahar Boua-fia (Algiers), Mohamed Chettibi (Algiers), Djamaleddine Nibouche (Medea), Abdelkader Moklati (Tipaza), Ahmed Benalia (Algiers), Omar Kaid (Blida), Messaad Krim (Blida). Funding Information: Funding This work was supported by AstraZeneca and led by the ACTION Group (Allies in Cardiovascular Trials Initiatives and Organized Networks), www.action-coeur.org. Funding Information: Conflict of interest All authors have completed the International Committee of Medical Journal Editors (ICMJE) Form for Disclosure of Potential Conflicts of Interest. Frédéric Lapostolle has received research grants, consultancy fees and honoraria from AstraZeneca, Merck-Serono, Roche, Boehringer-Ingelheim, Bayer, The Medicines Company, Correvio, Daiichi-Sankyo, and Eli-Lilly. Arnoud W. van ‘t Hof has received research grants, consultancy fees and honoraria from AstraZeneca, Medtronic, Daiichi-Sankyo, and Iroko Cardio. Christian W. Hamm has received research grants, consultancy fees, and honoraria from AstraZeneca, Daiichi-Sankyo, Lilly, Sanofi-Aventis, and Boehringer-Ingelheim. Patrick Ecollan has received consultancy fees from AstraZeneca, Abbott Vascular, Eli-Lilly, Sanofi-Aventis, and Biomérieux. Jean-Philippe Collet has received research grants from Bristol-Myers Squibb; consulting fees from Bristol-Myers Squibb, Eli Lilly, and Sanofi-Aventis; and lecture fees from Bristol-Myers Squibb and Sanofi-Aventis. Johanne Silvain has received research grants from Fédération Française de Cardiologie and Société Française de Cardi-ologie; consultancy fees and honoraria from Amgen, Algorythm As-traZeneca, Bayer, Gilead Science and Sanofi-Aventis; and travel support from Amgen, AstraZeneca, Bayer and Bristol-Myers Squibb. Jens Flensted Lassen has received honoraria from AstraZeneca. Leonardo Bolognese has received consultancy fees and honoraria from Astra-Zeneca, Daiichi-Sankyo, Eli-Lilly, Menarini Ind Farma, and Abbott. Warren J. Cantor has received honoraria from AstraZeneca. Mohamed Chettibi has received support from AstraZeneca (study investigator). Shaun G. Goodman has received support from AstraZeneca Canada (National [Canada] Coordinator) and consultancy fees and honoraria from AstraZeneca, Eli-Lilly, and Sanofi. Christopher J. Hammett has received research grants from AstraZeneca and consultancy fees and honoraria from AstraZeneca, Eli-Lilly, Bayer Healthcare, Boehringer-Ingelheim, Amgen, and The Medicines Company. Magnus Janzon has received support from AstraZeneca (National Coordinating Investigator) and Pfizer. Robert Storey has received research grants, consultancy fees and honoraria from AstraZeneca; research grants and consultancy fees from PlaqueTec; consultancy fees from Actelion/Idorsia, Avacta, Bayer, Bristol-Myers Squibb, Pfizer, Novartis, and The Medicines Company. Jur ten Berg has received research grants, consultancy fees and honoraria from AstraZeneca. Uwe Zeymer has received research grants from Daiichi-Sankyo, Eli-Lilly, Novartis and Sanofi and consultancy fees and honoraria from AstraZeneca, Bayer Healthcare, The Medicines Company, Daiichi-Sankyo, Eli-Lilly, Novartis, Sanofi, Boehringer-Ingelheim, and Merck-Sharp and Dohme. Gilles Montale-scot has received research grants (institution) from ADIR, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Celladon, Daiichi-Sankyo, Eli-Lilly, ICAN, Fédération Française de Cardiologie, Medtronic, Merck-Sharp and Dohme, Pfizer, Sanofi-Aventis, and The Medicines Company and consultancy fees from Am-gen, AstraZeneca, Bayer, Berlin Chimie AG, Boehringer-Ingelheim, Bristol-Myers Squibb, Beth Israel Deaconess Medical, Brigham Women’s Hospital, Cardiovascular Research Foundation, CME Resources, Daiichi-Sankyo, Eli-Lilly, Europa, Elsevier, Fondazione Anna Maria Sechi per il Cuore, Gilead, Janssen, Lead-Up, Menarini, Merck-Sharp and Dohme, Pfizer, Sanofi-Aventis, The Medicines Company, TIMI Study Group, and WebMD. Muriel Licour and Anne Tsatsaris are employees of AstraZeneca, while Angel Cequier, Béla Merkely, Kurt Hu-ber, Olivier Stibbe, and Wim M.J.M. Heutz have nothing to disclose. Publisher Copyright: © 2018, Springer Nature Switzerland AG.

PY - 2019/4

Y1 - 2019/4

N2 - BackgroundMorphine adversely impacts the action of oral adenosine diphosphate (ADP)-receptor blockers in ST-segment elevation myocardial infarction (STEMI) patients, and is possibly associated with differing patient characteristics. This retrospective analysis investigated whether interaction between morphine use and pre-percutaneous coronary intervention (pre-PCI) ST-segment elevation resolution in STEMI patients in the ATLANTIC study was associated with differences in patient characteristics and management.MethodsATLANTIC was an international, multicenter, randomized study of treatment in the acute ambulance/hospital setting where STEMI patients received ticagrelor 180mgmorphine. Patient characteristics, cardiovascular history, risk factors, management, and outcomes were recorded.ResultsOpioids (97.6% morphine) were used in 921 out of 1862 patients (49.5%). There were no significant differences in age, sex or cardiovascular history, but more morphine-treated patients had anterior myocardial infarction and left-main disease. Time from chest pain to electrocardiogram and ticagrelor loading was shorter with morphine (both p=0.01) but not total ischemic time. Morphine-treated patients more frequently received glycoprotein IIb/IIIa inhibitors (p=0.002), thromboaspiration and stent implantation (both p

AB - BackgroundMorphine adversely impacts the action of oral adenosine diphosphate (ADP)-receptor blockers in ST-segment elevation myocardial infarction (STEMI) patients, and is possibly associated with differing patient characteristics. This retrospective analysis investigated whether interaction between morphine use and pre-percutaneous coronary intervention (pre-PCI) ST-segment elevation resolution in STEMI patients in the ATLANTIC study was associated with differences in patient characteristics and management.MethodsATLANTIC was an international, multicenter, randomized study of treatment in the acute ambulance/hospital setting where STEMI patients received ticagrelor 180mgmorphine. Patient characteristics, cardiovascular history, risk factors, management, and outcomes were recorded.ResultsOpioids (97.6% morphine) were used in 921 out of 1862 patients (49.5%). There were no significant differences in age, sex or cardiovascular history, but more morphine-treated patients had anterior myocardial infarction and left-main disease. Time from chest pain to electrocardiogram and ticagrelor loading was shorter with morphine (both p=0.01) but not total ischemic time. Morphine-treated patients more frequently received glycoprotein IIb/IIIa inhibitors (p=0.002), thromboaspiration and stent implantation (both p

KW - DOUBLE-BLIND

KW - ASSOCIATION

KW - REPERFUSION

KW - PRASUGREL

KW - OUTCOMES

KW - INSIGHTS

KW - TRIAL

U2 - 10.1007/s40256-018-0305-0

DO - 10.1007/s40256-018-0305-0

M3 - Article

C2 - 30353444

SN - 1175-3277

VL - 19

SP - 173

EP - 183

JO - American Journal of Cardiovascular Drugs

JF - American Journal of Cardiovascular Drugs

IS - 2

ER -